Abstract
The promising results obtained with the HIV-1 Tat-based vaccines in mice, monkeys and humans, a better understanding of Tat immunomodulatory functions, as well as evidence that vaccination with trimeric V2 loop-deleted HIV-1 Env induces cross-clade neutralizing antibodies led to the rational design of a novel vaccine based on the combination of Tat and V2-deleted Env.
MeSH terms
-
AIDS Vaccines / adverse effects
-
AIDS Vaccines / genetics
-
AIDS Vaccines / immunology*
-
Adjuvants, Immunologic
-
Animals
-
Clinical Trials, Phase I as Topic
-
Gene Products, env / genetics
-
Gene Products, env / immunology*
-
Gene Products, tat / genetics
-
Gene Products, tat / immunology*
-
HIV Antibodies / blood
-
HIV-1 / immunology*
-
Humans
-
Macaca fascicularis
-
Male
-
Mice
-
Models, Animal
-
Neutralization Tests
-
Vaccines, Combined / adverse effects
-
Vaccines, Combined / genetics
-
Vaccines, Combined / immunology
-
Vaccines, Subunit / adverse effects
-
Vaccines, Subunit / genetics
-
Vaccines, Subunit / immunology
-
Vaccines, Synthetic / adverse effects
-
Vaccines, Synthetic / genetics
-
Vaccines, Synthetic / immunology
-
env Gene Products, Human Immunodeficiency Virus
-
tat Gene Products, Human Immunodeficiency Virus
Substances
-
AIDS Vaccines
-
Adjuvants, Immunologic
-
Gene Products, env
-
Gene Products, tat
-
HIV Antibodies
-
Vaccines, Combined
-
Vaccines, Subunit
-
Vaccines, Synthetic
-
env Gene Products, Human Immunodeficiency Virus
-
gp140 envelope protein, Human immunodeficiency virus 1
-
tat Gene Products, Human Immunodeficiency Virus